3 results match your criteria: "V.I. Razumovskiy Saratov State Medical University.[Affiliation]"
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.
PLoS One
March 2022
Clinical research department, JSC BIOCAD, Saint Petersburg, Russia.
Article Synopsis
- The study aimed to compare the effectiveness, safety, and pharmacokinetics of BCD-057 with the well-known drug adalimumab (iADA) for treating moderate to severe plaque psoriasis.
- A total of 346 patients participated, with 60% of BCD-057 users achieving significant improvement at week 16, showing both drugs are similarly effective over time.
- Both treatments exhibited comparable safety profiles, and switching from iADA to BCD-057 did not impact the patients' immune response, confirming their similarity.
Steroidogenic factor 1 (SF1, NR5A1) is a nuclear receptor that regulates multiple genes involved in adrenal and gonadal development, steroidogenesis, and the reproductive axis. Human mutations in SF1 were initially found in patients with severe gonadal dysgenesis and primary adrenal failure. However, more recent case reports have suggested that heterozygous mutations in SF1 may also be found in patients with 46,XY partial gonadal dysgenesis and underandrogenization but normal adrenal function.
View Article and Find Full Text PDFBackground: Cryptorchidism is associated with the risk of infertility and can be a symptom of congenital sexual maldevelopment.
Aim: To assess the functional status of the pituitary gland and sexual glands in boys aged 16 months with bilateral inguinal cryptorchidism and to reveal the congenital sexual maldevelopment during minipuberty.
Methods: Twenty-one boys aged 16 months (the minipuberty period) with isolated bilateral inguinal cryptorchidism and 40 healthy boys aged 23 months (the control group) were examined.